Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 9Other solid neoplasm 2Thoracic 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Neuroblastoma 1Neoplasms 1Carcinoma, Hepatocellular 1Brain Neoplasms 1

Interventions

pembrolizumab 93Nivolumab 61Docetaxel 55Cyclophosphamide 49enzalutamide 44Magnetic Resonance Spectroscopy 33Ipilimumab 33Gemcitabine 32Abiraterone Acetate 30Prednisone 29fludarabine 28Everolimus 27Paclitaxel 25Cisplatin 24Radiotherapy 23Carboplatin 23Sunitinib 22cabozantinib 21atezolizumab 20Radiosurgery 20Specimen Handling 19Sorafenib 18Bevacizumab 18pazopanib 17bicalutamide 17abiraterone 17Biopsy 15temsirolimus 14darolutamide 14apalutamide 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Trabectedin × Genitourinary × Clear all
NCT01453283 2017-07-02

Tabectedin to Treat Children and Adolescents With Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
12 enrolled
CNSGastrointestinalGenitourinarySarcoma

Brain Neoplasms, Carcinoma, Hepatocellular, Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡